AbbVie Inc. (NYSE:ABBV – Get Free Report) has been given a consensus rating of “Moderate Buy” by the thirty ratings firms that are currently covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation, twenty-three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $279.86.
A number of equities research analysts have weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a research report on Thursday, October 8th. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. BMO Capital Markets increased their price objective on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. HSBC increased their price objective on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Finally, Citigroup lifted their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th.
Read Our Latest Report on AbbVie
AbbVie Trading Up 1.4%
Shares of NYSE:ABBV opened at $294.80 on Friday. The business has a 50-day moving average price of $269.35 and a 200 day moving average price of $237.23. The company has a market capitalization of $520.85 billion, a price-to-earnings ratio of 83.28, a PEG ratio of 1.33 and a beta of 0.24. AbbVie has a 12-month low of $190.75 and a 12-month high of $298.74.
AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.73 by $0.09. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. During the same period in the previous year, the firm earned $1.86 EPS. AbbVie’s revenue was up 10.3% on a year-over-year basis. As a group, equities research analysts predict that AbbVie will post 13.92 earnings per share for the current fiscal year.
AbbVie Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.
Key AbbVie News
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
- Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
- Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
- Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
- Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3
Insider Activity at AbbVie
In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On AbbVie
Several hedge funds have recently bought and sold shares of the company. Burk Holdings LLC purchased a new position in AbbVie in the 2nd quarter valued at $30,000. Marquette Asset Management LLC increased its stake in AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after buying an additional 48 shares during the period. Principia Wealth Advisory LLC increased its stake in AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after buying an additional 44 shares during the period. Merkkuri Wealth Advisors LLC purchased a new position in AbbVie during the 1st quarter worth $34,000. Finally, IMG Wealth Management Inc. raised its position in AbbVie by 3,060.0% during the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after buying an additional 153 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.
AbbVie Company Profile
AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.
The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.
Featured Stories
- Five stocks we like better than AbbVie
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
